Yvonne Bombard

PhD, BSc

Scientist, Li Ka Shing Knowledge Institute

Biography

Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation.  Her research focuses on evaluating the adoption of new genomic technologies in clinical practice. She also conducts public and patient engagement research to advance health technology assessment and health service delivery. Dr. Bombard is active in numerous international policy advisory committees; her research informs policy development in this area.  In 2014, Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research in 2011. Recently, she has been awarded a CIHR Foundation grant as an Early Career Investigator, and she holds a CIHR New Investigator Award.

Dr. Bombard holds a Fellowship from Yale University (Health Policy), a Fellowship from the Memorial Sloan-Kettering Cancer Center (Cancer Genomics) and a Fellowship from the University of Toronto (Health Services Research).

Recent Publications

  1. Armsby, AJ, Bombard, Y, Garrison, NA, Halpern-Felsher, BL, Ormond, KE. Attitudes of Members of Genetics Professional Societies Toward Human Gene Editing. CRISPR J. 2019;2 (5):331-339. doi: 10.1089/crispr.2019.0020. PubMed PMID:31599688 .
  2. Shickh, S, Clausen, M, Mighton, C, Gutierrez Salazar, M, Zakoor, KR, Kodida, R et al.. Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open. 2019;9 (10):e031092. doi: 10.1136/bmjopen-2019-031092. PubMed PMID:31594892 .
  3. Ormond, KE, Bombard, Y, Bonham, VL, Hoffman-Andrews, L, Howard, H, Isasi, R et al.. The clinical application of gene editing: ethical and social issues. Per Med. 2019;16 (4):337-350. doi: 10.2217/pme-2018-0155. PubMed PMID:31331245 .
  4. Mighton, C, Charames, GS, Wang, M, Zakoor, KR, Wong, A, Shickh, S et al.. Correction: Variant classification changes over time in BRCA1 and BRCA2. Genet. Med. 2019;21 (10):2406-2407. doi: 10.1038/s41436-019-0526-x. PubMed PMID:31043710 .
  5. Mighton, C, Charames, GS, Wang, M, Zakoor, KR, Wong, A, Shickh, S et al.. Variant classification changes over time in BRCA1 and BRCA2. Genet. Med. 2019;21 (10):2248-2254. doi: 10.1038/s41436-019-0493-2. PubMed PMID:30971832 .
  6. Bombard, Y, Brothers, KB, Fitzgerald-Butt, S, Garrison, NA, Jamal, L, James, CA et al.. The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results. Am. J. Hum. Genet. 2019;104 (4):578-595. doi: 10.1016/j.ajhg.2019.02.025. PubMed PMID:30951675 PubMed Central PMC6451731.
  7. Allyse, M, Bombard, Y, Isasi, R, Michie, M, Musunuru, K, Ormond, KE et al.. What do we do now?: Responding to claims of germline gene editing in humans. Genet. Med. 2019;21 (10):2181-2183. doi: 10.1038/s41436-019-0492-3. PubMed PMID:30914827 .
  8. Mighton, C, Carlsson, L, Clausen, M, Casalino, S, Shickh, S, McCuaig, L et al.. Development of patient "profiles" to tailor counseling for incidental genomic sequencing results. Eur. J. Hum. Genet. 2019;27 (7):1008-1017. doi: 10.1038/s41431-019-0352-2. PubMed PMID:30846854 .
  9. Bombard, Y, Mighton, C. Recontacting clinical genetics patients with reclassified results: equity and policy challenges. Eur. J. Hum. Genet. 2019;27 (4):505-506. doi: 10.1038/s41431-018-0313-1. PubMed PMID:30568242 PubMed Central PMC6460896.
  10. Bombard, Y, Baker, GR, Orlando, E, Fancott, C, Bhatia, P, Casalino, S et al.. Engaging patients to improve quality of care: a systematic review. Implement Sci. 2018;13 (1):98. doi: 10.1186/s13012-018-0784-z. PubMed PMID:30045735 PubMed Central PMC6060529.
Search PubMed

Affiliations & Other Activities

  • Associate Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Chair, American Society of Human Genetics’ Duty to Recontact Guidelines Workgroup
  • Co-lead, Societal Values and Patient Engagement Program, the Canadian Centre for Applied Research in Cancer Control
  • Member, Ontario Genetics Advisory Committee, Health Quality Ontario
  • Member, Provincial Council for Maternal and Child Health’s Prenatal Screening Advisory Committee
  • Member, Provincial Council for Maternal and Child Health’s Maternal-Child Screening Committee (2016-2017)
  • Member, Steering Committee of the Canadian Coalition for Genetic Fairness
  • Visiting Investigator, Memorial Sloan Kettering Cancer Center, Clinical Genetics Service (2013-2016)
  • Chair, American Society of Human Genetics’ Social Issues Committee (2014-2015, 2017-2018)
  • Chair, European Huntington Disease Network’s Discrimination Working Group (2009-2010)
  • Member, Cancer Quality Council of Ontario’s Personalized Medicine Steering Committee (2010-2011)
  • Member, Cancer Care Ontario’s Patient Experience and Performance Committee (2013-2015)
  • Member, Patient and Citizen Involvement Working Group, Health Technology Assessment International
  • Member, Ethics Working Group, Health Technology Assessment International
X